Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer

Authors Menis J, Twelves C

Published Date August 2011 Volume 2011:3 Pages 101—111

DOI http://dx.doi.org/10.2147/BCTT.S21741

Published 26 August 2011

J Menis1, C Twelves2
1Department of Oncology, University Hospital Santa Maria della Misericordia, Udine, Italy; 2Leeds Cancer Research UK Centre, University of Leeds and St James's Institute of Oncology, Leeds, UK

Abstract: Although metastatic breast cancer remains essentially incurable, many patients previously treated with an anthracycline, taxane, and capecitabine are relatively fit and keen to receive further therapy. Several drugs are used in this setting, but with little evidence of clinically relevant benefit, and none have previously shown improved survival. Eribulin (Halaven®) is a nontaxane tubulin-binding agent with a novel mode of action, and was recently approved by the European Medicines Agency and US Food and Drug Agency as a single agent for patients with heavily pretreated metastatic breast cancer. This review provides an overview of the discovery, and preclinical and clinical development of eribulin, culminating in the recently published EMBRACE metastatic breast cancer study.

Keywords: eribulin, metastatic breast cancer, pretreated
Corrigendum

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Optic disc size and progression of visual field damage in patients with normal-tension glaucoma

Hayamizu F, Yamazaki Y, Nakagami T, Mizuki K

Clinical Ophthalmology 2013, 7:807-813

Published Date: 3 May 2013

Role of pertuzumab in the treatment of HER2-positive breast cancer

Hubalek M, Brantner C, Marth C

Breast Cancer: Targets and Therapy 2012, 4:65-73

Published Date: 28 May 2012

Respiratory management of the preterm newborn in the delivery room

Abdel-Hady H, Nasef N

Research and Reports in Neonatology 2012, 2:39-53

Published Date: 28 May 2012

Corrigendum

Menis J, Twelves C

Breast Cancer: Targets and Therapy 2012, 4:1-2

Published Date: 30 December 2011

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009